Please assess the completion status of the following clinical trial:

Trial Title: A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has a history of migraine with or without aura for more than one year, with between 2 and 8 moderate to severe attacks per month~* Patient is currently taking at least 50 mg topiramate daily for migraine prophylaxis~* Patient can distinguish between migraine and other types of headache~* Patient agrees to remain abstinent or use effective birth control during the study~Exclusion Criteria:~* Patient is pregnant or breast-feeding~* Patient has a history of mostly mild migraines or migraines that resolve within 2 hours~* Patient has more than 15 headache-days per month or has taken medication for acute headache on more than 10 days per month in the 3 months prior to screening.~* Patient was \> 50 years old at age of migraine onset~* Patient has history of heart disease~* Patient has uncontrolled hypertension~* Patient has had cancer within 5 years of screening (excepting certain skin and cervical cancers)~* Patient has started taking Selective Serotonin Reuptake Inhibitors (SSRIs) or Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) or has changed doses within 3 months of screening~* Patient is taking more than one other migraine prophylactic medication~* Patient has repeatedly failed to respond to or tolerate rizatriptan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Treatment Sequence A: rizatriptan, rizatriptan, placebo
- B (Type: EXPERIMENTAL): Sequence B: rizatriptan, placebo, rizatriptan
- C (Type: EXPERIMENTAL): Sequence C: placebo, rizatriptan, rizatriptan

Based on this trial design, predict the completion outcome and termination type (if applicable).